Skip to main content
OpenTrials
Completed

NCT Number: NCT04605315

Indications and Outcomes in Kidney-ureteral Pediatric Lithiasis: Experience of Parma

Incidence of paediatric urolithiasis is increasing in Europe and North America. Nowadays the management of stone disease is a common practice in not endemic country. The surgical's treatment is based on similar techniques as for adults. In the last years due to miniaturization of endoscopic instruments endourology has become the best approach to treat urinary stones in children. The investigators have retrospectively reviewed experience from 01/01/2000 to 28/02/2019 in children ≤ 16 years old affected by urinary stones who underwent rigid and flexible ureterorenoscopy and pecutaneous nephrolitotripsy procedures and recorded clinical data, overall success rate and complication.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pediatric ALL Calculi Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Precursor Cell Lymphoblastic Leukemia-Lymphoma Stone, Urinary Urinary Calculi Urogenital Diseases Urolithiasis Urologic Diseases

Age range

0 year–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

AOU Parma

Parma, 43125, Italy

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 0-17 yrs old, urinary stones (kidney, ureteral, not bladder), with or without malformations or metabolic diseases

Exclusion criteria

  • none

Treatment and study plan

Primary outcomes

  1. stone free rate

    Time frame: immediately

    no stones or residual fragment < 4 mm

  2. stone free rate

    Time frame: 3 months follow up

    no stones or residual fragment < 4 mm

  3. complication rate

    Time frame: immediately

    clavien-dindo classification

  4. complication rate

    Time frame: 3 months follow up

    clavien-dindo classification

Sponsors and collaborators

Lead sponsor

Azienda Ospedaliero-Universitaria di Parma

Other

Registry information

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Oct 28, 2020
Registry last updated
Oct 30, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.